To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
227 Current news of Novartis
rss
Ablynx's partner shows that a nanobody can elicit superior anti-tumour efficacy compared to conventional monoclonal antibody approaches
04-05-2012
Ablynx noted that a paper on a novel tetrameric Nanobody® agonist (TAS266) targeting Death Receptor 5 (DR5), a key receptor target on cancer cells across a number of tumour types, was presented at the American Association for Cancer Research Annual Meeting in Chicago by Novartis. The ability ...
Ablynx receives milestone payment as collaborator receives IND approval for a nanobody in oncology
04-03-2012
Ablynx announced that it has received a €400,000 milestone payment from its collaboration with Novartis. The payment was triggered by the approval of an Investigational New Drug (IND) application from the U.S. Food and Drug Administration for the Phase I clinical trial for a Nanobody® ...
Pivotal study confirms potential of Novartis candidate vaccine Bexsero to help protect infants against meningococcal serogroup B disease
02-10-2012
The Journal of the American Medical Association (JAMA) published a study that shows Bexsero induced a robust immune response against meningococcal B disease in the vast majority of infants vaccinated. These results also show that Bexsero can fit into various vaccination schedules in the first ...
Novartis drug Signifor recommended by CHMP for EU approval to treat patients with Cushing's disease
01-24-2012
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Signifor® (SOM230, pasireotide) for the treatment of Cushing's disease. There are currently no approved medicines in the European Union (EU) targeting Cushing's ...
Sandoz initiates two more Phase III biosimilar trials
01-20-2012
Sandoz announced that it has initiated two milestone Phase III clinical trials - one for biosimilar filgrastim (Amgen's Neupogen®) in the US market, the other for its global pegfilgrastim development program (Amgen's Neulasta®).The filgrastim study is to evaluate the efficacy and safety of ...
Novartis receives approval for Lucentis and launches Galvus in China
01-19-2012
Novartis announced that it received regulatory approval in China from the State Food and Drug Administration (SFDA) for Lucentis® (ranibizumab) to treat wet (neovascular) age-related macular degeneration (AMD), and is launching Galvus® (vildagliptin), an oral treatment for patients with type ...
Novartis to restructure US business
US General Medicines restructuring results in reduction of 1,960 positions
01-16-2012
Novartis Pharmaceuticals announced that the company plans to strengthen its long-term competitive position in anticipation of the Diovan® (valsartan) patent expiration and an expected reduction in demand for Rasilez®/Tekturna® (aliskiren) following termination of the ALTITUDE clinical study. ...
Novartis announces termination of ALTITUDE study with Rasilez/ Tekturna in high-risk patients with diabetes and renal impairment
Committee overseeing study identified higher adverse events when Rasilez/Tekturna was added to an ACE or ARB drug in this patient population
12-22-2011
Novartis announced that following the seventh interim review of data from the ALTITUDE study with Rasilez®/Tekturna® (aliskiren), a decision to terminate the trial has been taken on the recommendation of the independent Data Monitoring Committee (DMC) overseeing the trial.The DMC concluded ...
Novartis pivotal study of Exjade shows significant reduction of iron overload in patients with non-transfusion-dependent thalassemia
12-19-2011
Results from THALASSA, the first pivotal placebo-controlled study examining the benefit of iron chelation with Exjade® (deferasirox) in patients with non-transfusion-dependent thalassemia (NTDT), show that Exjade can significantly reduce iron overload. These data were presented at the 53rd ...
Novartis highlights advances for patients with breast cancer and hematological diseases with over 160 SABCS and ASH abstracts
12-07-2011
Novartis will showcase more than one hundred and sixty presentations on data from its oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases. The CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) ...
